An Open-label, Multicenter, Non-randomized, Dose Escalation Phase 1 Trial to Evaluate Safety and Tolerability of INCSHR01210 in Subjects With Advanced Solid Tumors

Trial Profile

An Open-label, Multicenter, Non-randomized, Dose Escalation Phase 1 Trial to Evaluate Safety and Tolerability of INCSHR01210 in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs INCSHR 1210 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 14 Sep 2017 Planned number of patients changed from 27 to 24.
    • 14 Sep 2017 Status changed from active, no longer recruiting to recruiting.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top